Skip to main content
Contact Us
Sign Up
Subscriber Sign In
English
日本語
navigation
Search
What We Do
Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
About Vantage
Editorial team
Products & Services
Consensus Forecasts
Pharma
EvaluatePharma
EvaluatePharma Vision
Custom Solutions
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Client Success
Customer Testimonials
Thought Leadership
English
日本語
About Us
Media Centre
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Policy & Pricing
Policy & Regulation
Pricing
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Proteolix
March 03, 2015
Amgen still in play with Endeavor to expand Kyprolis
July 07, 2014
No respite for private biotech takeovers
August 27, 2013
Level-headed negotiating hands Onyx to Amgen at last
January 10, 2013
Friendly FDA ups number of NMEs
December 12, 2011
Carfilzomib shifting to the slow lane
December 02, 2011
EP Vantage Interview - BerGenBio close to securing Series A funds
November 30, 2011
Onyx making nice progress but takeover rumours seem wide of the mark
November 15, 2011
Geron exits embryonic stem cell stage
October 11, 2011
Cleave secures hefty investment on promise of personalised medicine
September 12, 2011
Event – Onyx could be in for Christmas bonuses
March 01, 2011
Daiichi pays handsome price for Plexxikon
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
July 31, 2019
Vantage Pharma, Biotech & Medtech Half-Year Review 2019
February 26, 2019
Vantage Pharma, Biotech and Medtech 2018 in Review
Editor's Picks
October 22, 2019
Shock revelation sees Biogen erase its aducanumab losses
October 22, 2019
Vertex’s double cystic fibrosis surprise
October 23, 2019
Bristol might play a role in front-line lung cancer after all
October 23, 2019
Bloated on arrival? Biotech's weightiest new issues
October 14, 2019
Uncovering biopharma’s hidden treasures
